These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Kurt H; Bueso-Ramos CE; Khoury JD; Routbort MJ; Kanagal-Shamanna R; Patel UV; Jorgensen JL; Wang SA; Ravandi F; DiNardo C; Luthra R; Medeiros LJ; Patel KP Am J Surg Pathol; 2018 May; 42(5):569-577. PubMed ID: 29635257 [TBL] [Abstract][Full Text] [Related]
5. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690 [TBL] [Abstract][Full Text] [Related]
7. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797 [TBL] [Abstract][Full Text] [Related]
8. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry. Yaman B; Kandiloğlu G; Akalin T Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683 [TBL] [Abstract][Full Text] [Related]
9. A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma. Catteau A; Girardi H; Monville F; Poggionovo C; Carpentier S; Frayssinet V; Voss J; Jenkins R; Boisselier B; Mokhtari K; Sanson M; Peyro-Saint-Paul H; Giannini C Acta Neuropathol Commun; 2014 Jun; 2():58. PubMed ID: 24889502 [TBL] [Abstract][Full Text] [Related]
10. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727 [TBL] [Abstract][Full Text] [Related]
11. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Loussouarn D; Le Loupp AG; Frenel JS; Leclair F; Von Deimling A; Aumont M; Martin S; Campone M; Denis MG Int J Oncol; 2012 Jun; 40(6):2058-62. PubMed ID: 22447191 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction. Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781 [TBL] [Abstract][Full Text] [Related]
13. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. Ihle MA; Fassunke J; König K; Grünewald I; Schlaak M; Kreuzberg N; Tietze L; Schildhaus HU; Büttner R; Merkelbach-Bruse S BMC Cancer; 2014 Jan; 14():13. PubMed ID: 24410877 [TBL] [Abstract][Full Text] [Related]
14. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas. Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954 [TBL] [Abstract][Full Text] [Related]
15. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma]. Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295 [No Abstract] [Full Text] [Related]
16. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. Gierke M; Sperveslage J; Schwab D; Beschorner R; Ebinger M; Schuhmann MU; Schittenhelm J J Cancer Res Clin Oncol; 2016 Jan; 142(1):89-100. PubMed ID: 26115961 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature. Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650 [TBL] [Abstract][Full Text] [Related]
19. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160 [TBL] [Abstract][Full Text] [Related]
20. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors. Hayashi Y; Sasaki H; Takeshita S; Nishikawa R; Nishikawa H; Arakawa A; Yamashita Y; Takahashi S; Sugiura-Ogasawara M Oncol Rep; 2014 Nov; 32(5):1815-9. PubMed ID: 25174456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]